Literature DB >> 21160660

Aberrant promoter methylation of p16 in colorectal adenocarcinoma in North Indian patients.

Pooja Malhotra1, Rakesh Kochhar, Kim Vaiphei, Jai Dev Wig, Safrun Mahmood.   

Abstract

AIM: To investigate p16 gene methylation and its expression in 30 patients with sporadic colorectal adenocarcinoma in a North Indian population.
METHODS: Methylation specific polymerase chain reaction was used to detect p16 gene methylation and immunohistochemistry was used to study the p16 expression in 30 sporadic colorectal tumors as well as adjoining and normal tissue specimens.
RESULTS: Aberrant promoter methylation of p16 gene was detected in 12 (40%) tumor specimens, whereas no promoter methylation was observed in adjoining and normal tissue. Immunohistochemistry showed expression of p16 protein in 26 (86.6%) colorectal tumors whereas complete loss of expression was seen in 4 (13.3%) and reduced expression was observed in 12 (40%) tumors. In the adjoining mucosa, expression of p16 was in 11 (36.6%) whereas no clear positivity for p16 protein was seen in normal tissue. There was a significant difference in the expression of p16 protein in tumor tissue and adjoining mucosa (P < 0.001). The methylation of the p16 gene had a significant effect on the expression of p16 protein (P = 0.021). There was a significant association of methylation of p16 gene with the tumor size (P = 0.015) and of the loss/reduced expression of p16 protein with the proximal site of the tumor (P = 0.047). Promoter methylation and expression of p16 had no relation with the survival of the patients (P > 0.05).
CONCLUSION: Our study demonstrated that promoter hypermethylation of the p16 gene results in loss/reduced expression of p16 protein and this loss/reduced expression may contribute to tumor enlargement.

Entities:  

Keywords:  Colorectal cancer; Immunohistochemistry; Methylation; Methylation specific polymerase chain reaction; p16

Year:  2010        PMID: 21160660      PMCID: PMC2998854          DOI: 10.4251/wjgo.v2.i7.295

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  45 in total

1.  Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia.

Authors:  S X Guo; T Taki; H Ohnishi; H Y Piao; K Tabuchi; F Bessho; R Hanada; M Yanagisawa; Y Hayashi
Journal:  Leuk Res       Date:  2000-01       Impact factor: 3.156

2.  Gene promoter hypermethylation in tumors and serum of head and neck cancer patients.

Authors:  M Sanchez-Cespedes; M Esteller; L Wu; H Nawroz-Danish; G H Yoo; W M Koch; J Jen; J G Herman; D Sidransky
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

3.  Methylation and expression of p16INK4 tumor suppressor gene in primary colorectal cancer tissues.

Authors:  Byung No Kim; Hirofumi Yamamoto; Kimimasa Ikeda; Bazarragchaa Damdinsuren; Yurika Sugita; Chew Yee Ngan; Yujiro Fujie; Minoru Ogawa; Taishi Hata; Masataka Ikeda; Masayuki Ohue; Mitsugu Sekimoto; Takushi Monden; Nariaki Matsuura; Morito Monden
Journal:  Int J Oncol       Date:  2005-05       Impact factor: 5.650

4.  Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma.

Authors:  A K El-Naggar; S Lai; G Clayman; J K Lee; M A Luna; H Goepfert; J G Batsakis
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

5.  Association between CpG island methylation and microsatellite instability in colorectal cancer.

Authors:  N Ahuja; A L Mohan; Q Li; J M Stolker; J G Herman; S R Hamilton; S B Baylin; J P Issa
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

6.  Hypermethylation of the p16 gene in nasopharyngeal carcinoma.

Authors:  K W Lo; S T Cheung; S F Leung; A van Hasselt; Y S Tsang; K F Mak; Y F Chung; J K Woo; J C Lee; D P Huang
Journal:  Cancer Res       Date:  1996-06-15       Impact factor: 12.701

7.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.

Authors:  J G Herman; A Merlo; L Mao; R G Lapidus; J P Issa; N E Davidson; D Sidransky; S B Baylin
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

8.  Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma.

Authors:  Po Zhao; Ying-Chuan Hu; Ian C Talbot
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

9.  p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma.

Authors:  Y Matsuda; T Ichida; J Matsuzawa; K Sugimura; H Asakura
Journal:  Gastroenterology       Date:  1999-02       Impact factor: 22.682

10.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more
  5 in total

1.  Environmental chemical exposures and human epigenetics.

Authors:  Lifang Hou; Xiao Zhang; Dong Wang; Andrea Baccarelli
Journal:  Int J Epidemiol       Date:  2011-12-13       Impact factor: 7.196

2.  Differential Expression of ADAM23, CDKN2A (P16), MMP14 and VIM Associated with Giant Cell Tumor of Bone.

Authors:  André Luis Giacometti Conceição; Erica Babeto; Natalia Maria Candido; Fernanda Craveiro Franco; Débora Aparecida Pires de Campos Zuccari; Jane Lopes Bonilha; José Antônio Cordeiro; Marilia Freitas Calmon; Paula Rahal
Journal:  J Cancer       Date:  2015-05-23       Impact factor: 4.207

3.  Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review.

Authors:  Muriel X G Draht; Danny Goudkade; Alexander Koch; Heike I Grabsch; Matty P Weijenberg; Manon van Engeland; Veerle Melotte; Kim M Smits
Journal:  Clin Epigenetics       Date:  2018-03-14       Impact factor: 6.551

4.  Prognostic and clinicopathological value of p16 protein aberrant expression in colorectal cancer: A PRISMA-compliant Meta-analysis.

Authors:  Ning Zhou; Quankai Gu
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

5.  Promoter and histone methylation and p16(INK4A) gene expression in colon cancer.

Authors:  Ebru Esin Yoruker; Ufuk Mert; Dursun Bugra; Sumer Yamaner; Nejat Dalay
Journal:  Exp Ther Med       Date:  2012-08-24       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.